Leerink Partners Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)

Leerink Partners initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report released on Thursday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $16.00 target price on the specialty pharmaceutical company’s stock.

Other research analysts also recently issued reports about the stock. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating on the stock. Guggenheim initiated coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, William Blair began coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Tenax Therapeutics Price Performance

TENX opened at $4.75 on Thursday. The company’s 50 day simple moving average is $3.79 and its 200-day simple moving average is $3.59. Tenax Therapeutics has a one year low of $2.77 and a one year high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($1.99) by $0.16. On average, equities analysts anticipate that Tenax Therapeutics will post -6.75 EPS for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.